Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LANADELUMAB Cause Urinary tract infection? 58 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 58 reports of Urinary tract infection have been filed in association with LANADELUMAB (TAKHZYRO). This represents 2.8% of all adverse event reports for LANADELUMAB.

58
Reports of Urinary tract infection with LANADELUMAB
2.8%
of all LANADELUMAB reports
6
Deaths
38
Hospitalizations

How Dangerous Is Urinary tract infection From LANADELUMAB?

Of the 58 reports, 6 (10.3%) resulted in death, 38 (65.5%) required hospitalization, and 3 (5.2%) were considered life-threatening.

Is Urinary tract infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LANADELUMAB. However, 58 reports have been filed with the FAERS database.

What Other Side Effects Does LANADELUMAB Cause?

Hereditary angioedema (1,343) Product dose omission issue (555) Weight decreased (361) Weight increased (353) Inappropriate schedule of product administration (318) Product use issue (229) Covid-19 (225) Injection site pain (201) Insurance issue (172) Drug ineffective (142)

What Other Drugs Cause Urinary tract infection?

ADALIMUMAB (6,375) LENALIDOMIDE (4,247) ETANERCEPT (3,915) OCRELIZUMAB (3,618) TOFACITINIB (3,179) METHOTREXATE (2,960) DALFAMPRIDINE (2,757) RITUXIMAB (2,579) CARBIDOPA\LEVODOPA (2,151) ABATACEPT (2,110)

Which LANADELUMAB Alternatives Have Lower Urinary tract infection Risk?

LANADELUMAB vs LANADELUMAB-FLYO LANADELUMAB vs LANREOTIDE LANADELUMAB vs LANSOPRAZOLE LANADELUMAB vs LANTHANUM LANADELUMAB vs LANTUS

Related Pages

LANADELUMAB Full Profile All Urinary tract infection Reports All Drugs Causing Urinary tract infection LANADELUMAB Demographics